Exciting news for investors interested in the booming cannabidiol (CBD) industry! Dragonfly Biosciences, a prominent CBD producer and distributor, is preparing for its upcoming listing on the Australian Securities Exchange (ASX). While the official listing date is yet to be announced, investors can expect an opportunity to be part of this rapidly growing sector.

Dragonfly Biosciences is dedicated to the production and distribution of cannabidiol, a non-intoxicating compound derived from the cannabis plant known for its potential therapeutic properties. With a focus on quality and innovation, Dragonfly Biosciences aims to provide high-quality CBD products to meet the growing demand in the market.

The issue price for Dragonfly Biosciences’ ordinary fully paid shares is set at AUD 0.20, and the security code assigned to the company is DRF. Through this initial public offering (IPO), Dragonfly Biosciences plans to raise $5,000,000 in capital. This presents an opportunity for investors to participate in the growth and expansion of the CBD industry.

The joint lead managers for Dragonfly Biosciences’ IPO are Finexia Securities Limited and Lazarus Corporate Finance Pty Ltd. These esteemed firms will play a crucial role in ensuring a smooth and successful listing process.

Dragonfly Biosciences’ specific GICS industry group is yet to be confirmed, reflecting the evolving nature of the CBD industry and its integration into the financial markets.

For more information about Dragonfly Biosciences and its upcoming listing, interested parties can visit the company’s website at https://dragonflybiosciences.com/ or contact Dragonfly Biosciences directly at 1300 886 103.

As the listing date approaches, it is important for investors to stay updated on any further announcements regarding Dragonfly Biosciences’ IPO. IPO Society will continue to provide the latest updates on this and other upcoming ASX listings, ensuring investors have access to the most current information.

Please note that the details provided are based on the available information, and it is advised to refer to the official offering documents and consult with financial advisors before making any investment decisions in the emerging CBD sector.